A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
This study has been terminated.
(Closed per Data Monitoring Committee due to toxicity & incomplete treatment of patients resulting in poor data.)
First Posted: February 13, 2006
Last Update Posted: August 12, 2016
Eli Lilly and Company
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):